Dr. Betty Murray examines whether women over 65 can safely start hormone replacement therapy, focusing on transdermal bioidentical estrogen. The Women's Health Initiative left older women without clear guidance. She describes a typical patient in her late 60s with sleep problems, declining bone density, and dementia concerns, and explains how modern transdermal methods differ from the oral estrogens used in that landmark study.
The 65+ age frontier. Is it too late to start hormone replacement therapy? So today I'm going to do a deep dive. I've been digging into this, and I'm actually working on a systematic review of the literature right now, which is nerd speak for digging in and actually writing a scientific article about where the gaps are in women's health and, and really how to make clinical decisions about hormones when we are living in an evidence vacuum. It isn't an accident. It's a legacy from the Women's Health Initiative that was— that basically left healthy women, older women particularly, in a clinical no man's land, forcing us to choose between mechanistic promises and/or historical fear. So I want you to imagine a woman in her early 70s, you know, maybe late 60s. She's vibrant, metabolically healthy, proactive, and she didn't miss the menopause conversation. She lived through its evolution, but now she's facing a set of new questions. Her sleep is fragmented. Her bone density is slipping. She carries maybe the Alzheimer's gene. Maybe she carries a little increased risk for dementia or is very concerned about dementia. And she goes to the doctor and asks, is it too late for me to do hormone replacement therapy, particularly transdermal estrogen? Right. Transdermal estrogen, just for everybody, that is a bioidentical form of estrogen. It is either in a cream, a patch, an oil, a pellet, or an injectable. And the transdermal form is very, very different than what was used in the Women's Health Initiative.
